Realizing Improved Outcomes in Advanced Prostate Cancer through Evolving Research and Emerging Treatment Paradigms: Challenges and Opportunities

Realizing Improved Outcomes in Advanced Prostate Cancer through Evolving Research and Emerging Treatment Paradigms: Challenges and Opportunities
Program Summary

The increasingly complex prostate cancer treatment milieu is marked by limited sequencing or combination trials, an increasingly complex understanding of disease pathophysiology and genomic profiling, and emerging therapeutics with novel mechanisms of action. Understanding the available treatments, both current and emerging, and how these agents interface with disease pathophysiology to drive a more personalized medicine approach remain significant challenges for clinicians who treat patients with advanced prostate cancer.



This engaging, interactive educational activity presented by nationally recognized experts is designed to help practicing clinicians apply best current practices to challenging cases. An overview of recent advances in treatment of advanced prostate cancer will be provided, along with a discussion on sequencing and combination strategies.
Learning Objectives:

1. Outline how a personalized approach to treatment, as it relates to the genetic landscape of prostate cancer, can impact patient prognosis and treatment selection

2. Formulate appropriate care plans for patients with advanced prostate cancer based on individual patient disease characteristics, including considerations of the best clinically relevant strategies for combining and sequencing therapies

3. Evaluate emerging treatment options for advanced prostate cancer based upon individual patient disease characteristics and treatment-related complications
Accreditation Information:

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this live activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this live activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this live activity for a maximum of one (1) continuing education unit(s) in Pharmacy.
Speaker List:

Daniel P. Petrylak, MD (Chair)
Professor of Medicine (Medical Oncology) and Urology
Co-director, Signal Transduction
Research Program
Yale School of Medicine
New Haven, CT

Nicklas Pfanzelter, MD (Co-Chair)
Assistant Professor of Medicine
Section of Medical Oncology
Division of Hematology, Oncology and Cell Therapy
Rush University Medical Center


Leonard Gomella, MD
Professor
Chair, Department of Urology
Director, Kimmel Cancer Center Network
Thomas Jefferson University


Ulka Vaishampayan, MD
Chair, Division of  Solid Tumor Oncology
Director of Phase I Therapeutics
Karmanos Cancer Institute
Charles Martin endowed Chair
Professor of Oncology
Wayne State University

William K. Oh, M.D.
Chief, Division of Hematology and Medical Oncology
Professor of Medicine and Urology
Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics
Icahn School of Medicine at Mount Sinai
Associate Director of Clinical Research
The Tisch Cancer Institute


Charles Ryan, MD
Professor of Clinical Medicine and Urology

Department of Medicine, UCSF
Program Leader, Genitourinary Medical Oncology, UCSF


Robert Dreicer, M.D., M.S., MACP, FASCO
Section Head Medical Oncology
Deputy Director, University of Virginia Cancer Center
Associate Director for Clinical Research
Co-Director Paul Mellon Urologic Cancer Institute

Please fill in this form to request a hospital meeting.

Your Contact Information

Meeting Specifics

 
This activity is supported by educational grants from Astellas Scientific and Medical Affairs, Inc. and Medivation Inc., a Pfizer Company, Bayer HealthCare Pharmaceuticals Inc., Clovis Oncology, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Sanofi Genzyme.

Categories: Hospital Events

Social Buttons